Physician profile
Derrick Ridley
NPI 1679530703
$2,213.68
in general payments reported to CMS, 2019-2025
18 companies · $155 in 2025
The $155 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $252 · 2021: $216 · 2022: $253 · 2023: $363 · 2024: $436 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.41 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $436.55 | 2019-2025 | Farxiga |
| Amgen INC. | $382.97 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $369.88 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $167.97 | 2019-2023 | Jot Dx |
| Boston Scientific Corporation | $158.29 | 2019-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $136.81 | 2020-2023 | |
| Actelion Pharmaceuticals US, INC. | $118.23 | 2024 | Uptravi, Opsumit |
| Irhythm Technologies, INC. | $98.13 | 2021-2023 | Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $68.91 | 2020-2024 | Xarelto |
| Scpharmaceuticals INC. | $55.44 | 2024 | |
| Sanofi-Aventis U.S. LLC | $36.79 | 2019-2022 | |
| Astellas Pharma US INC | $34.09 | 2019-2022 | |
| Medtronic Vascular, INC. | $32.04 | 2019 | |
| Pfizer INC. | $30.01 | 2019-2021 | |
| Esperion Therapeutics, INC. | $28.65 | 2023-2024 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $24.44 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $18.60 | 2025 | Attruby |
| Azurity Pharmaceuticals, INC. | $15.88 | 2024 | Edarbyclor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Ridley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.